GW Pharmaceuticals claims Epidiolex would price $32,500 each year

GW Pharmaceuticals claims Epidiolex would price $32,500 each year

GW Pharmaceuticals has revealed the expense of Epidiolex, the initial cannabis-based medicine which has been authorized by the United States Food and Drug management. In line with the drug manufacturer, Epidiolex would price each client on average $32,000 each year.

British-based GW Pharmaceuticals made the revelation for a call with investors week that is last.

Treatment plan for unusual type of epilepsy

Epidiolex is created as treatment for two rare types of childhood epilepsy: Dravet problem and Lennox-Gastaut problem. Both of these medical conditions are described as regular and hard-to-treat seizures. Read more